Table 3 Clinical characteristics and islet function indexes of LADA-2 subjects according to RDW tertiles
I(11.2–12.4%) | II(12.5–12.9%) | III(13.0–18%) | P | |
|---|---|---|---|---|
n | 117 | 118 | 116 | |
male (%) | 69(59.0%) #Δ | 53(44.9%)*Δ | 42(36.2%)*# | < 0.001 |
Age (years) | 56.8 ± 13.9#Δ | 58.2 ± 14.5*Δ | 59.1 ± 14.2*# | < 0.001 |
duration(years) | 6.6 ± 4.1#Δ | 7.0 ± 4.2*Δ | 7.3 ± 4.1*# | 0.018 |
BMI (kg/m2) | 22.9 ± 3.9 | 23.9 ± 4.5 | 23.8 ± 4.0 | 0.074 |
SBP (mmHg) | 128.3 ± 18.1 | 129.4 ± 17.9 | 129.1 ± 18.5 | 0.317 |
DBP (mmHg) | 70.9 ± 17.8 | 71.4 ± 17.9 | 71.2 ± 17.3 | 0.562 |
TG (mmol/L) | 1.8 ± 0.5#Δ | 1.6 ± 0.5*Δ | 1.4 ± 0.6*# | 0.021 |
TC (mmol/L) | 4.3 ± 0.6 | 4.5 ± 0.7 | 4.4 ± 0.8 | 0.263 |
LDL (mmol/L) | 2.7 ± 0.6 | 2.8 ± 0.6 | 2.8 ± 0.6 | 0.094 |
HDL (mmol/L) | 1.0 ± 0.4 | 1.0 ± 0.4 | 1.0 ± 0.3 | 0.173 |
GAD(IU/ml) | 56.7 ± 52.1 | 54.8 ± 42.9 | 59.9 ± 51.6 | 0.316 |
ALT (U/L) | 19.4 ± 12.8 | 21.8 ± 13.2 | 22.4 ± 13.0 | 0.219 |
AST (U/L) | 19.7 ± 12.1 | 21.8 ± 11.9 | 20.1 ± 12.4 | 0.594 |
Cr (umol/L) | 60.7 ± 28.9#Δ | 63.1 ± 29.1*Δ | 66.7 ± 29.2*# | 0.038 |
SUA (umol/L) | 318.9 ± 146.7 | 331.1 ± 150.6 | 321.2 ± 149.9 | 0.297 |
HbA1c(%) | 9.1 ± 1.9 | 9.1 ± 2.0 | 9.0 ± 2.1 | 0.062 |
FCP (ng/ml) | 1.6 ± 0.6#Δ | 1.7 ± 0.6*Δ | 1.8 ± 0.7*# | 0.021 |
P2hCP (ng/ml) | 1.9 ± 0.7#Δ | 2.4 ± 0.7*Δ | 2.8 ± 0.7*# | < 0.001 |
Use of insulin(%) | 47(40.2%) | 45(38.1%) | 44(38.0%) | 0.197 |
HOMA-IR | 1.6 ± 0.5 | 1.7 ± 0.6 | 1.6 ± 0.6 | 0.315 |
HOMA-β | 12.7 ± 5.8#Δ | 14.8 ± 5.9*Δ | 16.7 ± 6.1*# | < 0.001 |